Recent Form 4 filings with the U.S. Securities and Exchange
Commission indicate that the management team of International Stem Cell
Corporation (OTCQB: ISCO) is bullish on the company. Form 4 is a Statement of
Changes of Beneficial Ownership of Securities which every officer, director or
holder of 10 percent (insiders) must file to report the acquisition or
disposition of a company’s non-derivative and derivative securities. Five Form
4s filed at the end of June this year report purchases of 239,534 shares.
Things appear to be looking up at ISCO. Could it be the imminent start of
clinical trials that has made insiders so sanguine?
The term ‘insider trading’ has come to mean the illegal
practice of using information, not available to the public, to execute trades.
However, it is neither immoral nor illegal for insiders to trade. So how can we
tell when insiders are trading on private information? A lot depends on the
circumstances. Sometimes it may be obvious; sometimes it is not. Therefore, to
increase transparency, the SEC requires that share purchases by insiders be
made public.
Previously, a Form 4 filing had to be made by the 10th day
of the month following the actual transaction. Now, the Sarbanes-Oxley Act of
2002 mandates that a Form 4 must be filed electronically via EDGAR within two
business days of each transaction. With regard to sales of shares by insiders,
there may be further filing requirements, perhaps because share sales may
signal adverse circumstances. A Form 144 must be filed by any insider (or
outsider), who intends to sell more than 500 shares or $10,000 worth of
restricted, unregistered securities within the next 90 days.
Share purchases by insiders, typically, signal good things
ahead. Since insiders know more about their company, they can spot valuation
anomalies in the market. Roger Martin, dean of the University of Toronto’s
Rotman School of Management has said that, in mapping out an investment
strategy, insider trading ‘is about the only thing I would pay attention to’.
Prof. Martin is the co-author, with A.G. Lafley, of the best-selling Playing to
Win: How Strategy Really Works that ‘outlines the strategic approach Lafley, in
close partnership with… Martin, used to double P&G’s sales, quadruple its
profits, and increase its market value by more than $100 billion’.
Backing that up is this Investopedia entry
(http://dtn.fm/A3pAv):
‘Nejat Seyhun, a renowned professor and researcher in the
field of insider trading at the University of Michigan found that when
executives bought shares in their own companies, the stock tended to outperform
the total market by 8.9% over the next 12 months. Conversely when they sold
shares, the stock underperformed the market by 5.4%.’
Widespread share purchases by managements across the board
are sure signs of a rising market. The Financial Times cites Ben Silverman,
research director of InsiderScore, which tracks insider trades:
“… in the past 30 years, there has been no time when the
market bottomed and rallied when it wasn’t preceded by a critical mass of
insider buying”. As the saying goes: actions speak louder than words.
International Stem Cell Corporation recently published the
results of a 12-month preclinical, non-human primate study. The data
demonstrates the safety and efficacy of the company’s proprietary ISC-hpNSC®
readily expandable neural stem cell derived treatment of Parkinson’s disease.
The results of the study were published in the academic journal Cell
Transplantation and end the preclinical stage of ISCO’s Parkinson’s disease
program. The data provides further evidence that parthenogenetic neural stem
cells can be effective in treating the symptoms of Parkinson’s disease and,
along with the previously revealed safety data, formed the basis of ISCO’s
application to the Australian regulatory authorities to move this program to
the clinical stage.
The Phase I clinical study is a dose escalation safety and preliminary
efficacy study of ISC-hpNSC®, intracranially transplanted into patients with
moderate to severe Parkinson’s disease. The open-label, single center,
uncontrolled clinical trial will evaluate three different dose regimens. A
total of 12 participants with moderate to severe Parkinson’s disease will be
treated. Following transplantation, the patients will be monitored for 12
months at specified intervals, to evaluate the safety and biologic activity of
ISC-hpNSC®. PET scans will be performed at baseline, as part of the screening
assessment, and at six and 12 months after surgical intervention. Clinical
responses compared to baseline after the administration of ISC-hpNSC® will be
evaluated using various neurological assessments such as the Unified Parkinson
Disease Rating Scale (UPDRS) and the Hoehn and Yahr rating scales. The study
will be performed at Royal Melbourne Hospital in Australia.
For more information, visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment